Avalon GloboCare and Qi Diagnostics agree to co-develop cannabis breathalyzer for impaired driving detection

Avalon GloboCare Corp.

Definitive agreement for co-development of VOC nanosensor-based point-of-care cannabis breathalyzer.
Total milestone payments up to $975,000 across four stages: data collection, prototype design, production, human testing.
Qi Diagnostics retains IP; Q&A (Avalon sub) earns up to 50% passive financial interest in IP upon all milestones.
Device aims to support real-time detection of cannabis-impaired driving for law enforcement and workplace safety.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.